给手术师的世界性翻译工具
腹腔镜手术采用微创技术，减少病人疼痛并缩短愈合时间。但史威茨博格发现，这项技术在世界范围内的应用遇到了两个难题——语言及距离。他将同我们分享，一个整合了视频会议技术的世界性翻译工具，如何能够有效地解决这些问题。
一个工具，可以解决手术中最危险的一个环节。
手术是每天都会发生的事情，但在其真正就开始前必须刺破人的皮肤，并且伴随着损坏其它部位的风险。在这个吸引人的演讲中，去找寻机械工程师尼古拉·贝格是如何利用物理升级一个叫做套管针的医疗工具并解除手术中最危险的一个环节的。
为什么基因治疗能成为消灭HIV的合理工具 - David Baltimore P2
本视频由科普中国和生物医学大讲堂出品
David Baltimore (Caltech) Part 2: Why Gene Therapy Might be a Reasonable Tool for Attacking HIV
Lecture Overview:
In this set of lectures, I describe the threat facing the world from the human immunodeficiency virus (HIV) and a bold proposal on how we might meet the challenge of eliminating this disease by engineering the immune system.
In part 1, I provide a broad introduction to viruses, describing their basic properties and my own history of studying the replication of RNA viruses which led to the discovery of reverse transcriptase. I also illustrate the distinguishing features of equilibrium viruses (e.g. the common cold) that have adapted to co-exist with their host and non-equilibrium viruses (e.g. HIV) that have recently jumped from another species, are not adapted to the new host, and which can lead to disastrous outcomes (e.g. loss of immune function with potential lethality in the case of HIV).
In part 2, I describe the growing health problem that is facing the world with the spread of HIV and the limitations of current drug therapies and vaccine strategies. We need new ideas for tackling this problem. Here and in the next segment, I describe bold strategies of using gene therapy to conquer HIV, The approach that I describe in this segment involves gene therapy to produce short hairpin RNAs (siRNA) that target the destruction of a critical co-receptor of HIV, which the viruses that needs to infect cells. I discuss initial proof-of-principle experiments that suggest this approach might be feasible and the next steps needed to develop this idea into a real therapy.
In this last segment, I describe another gene therapy strategy for HIV in which we propose to develop antibody-like proteins that can be expressed by a patient's B cells and will target the HIV virus for destruction. To achieve this objective, hematopoietic (blood) stem cells must to be targeted with the gene, which will ultimately develop into B cells that express the therapeutic molecule. The ultimate goal is to produce a life-long supply of anti-HIV neutralizing antibodies. In this lecture, I describe the molecular methods underlying this strategy and a development path from proof-of-principle studies in mouse to safe trials in humans. This project receives funding from the Bill and Melinda Gates Foundation.
Speaker Bio:
After serving as President of the California Institute of Technology for nine years, in 2006 David Baltimore was appointed President Emeritus and the Robert Andrews Millikan Professor of Biology. Born in New York City, he received his B.A. in Chemistry from Swarthmore College in 1960 and a Ph.D. in 1964 from Rockefeller University, where he returned to serve as President from 1990-91 and faculty member until 1994.
For almost 30 years, Baltimore was a faculty member at Massachusetts Institute of Technology. While his early work was on poliovirus, in 1970 he identified the enzyme reverse transcriptase in tumor virus particles, thus providing strong evidence for a process of RNA to DNA conversion, the existence of which had been hypothesized some years earlier. Baltimore and Howard Temin (with Renato Dulbecco, for related research) shared the 1975 Nobel Prize in Physiology or Medicine for their discovery, which provided the key to understanding the life-cycle of HIV. In the following years, he has contributed widely to the understanding of cancer, AIDS and the molecular basis of the immune response. His present research focuses on control of inflammatory and immune responses as well as on the use of gene therapy methods to treat HIV and cancer in a program called "Engineering Immunity".
Baltimore played an important role in creating a consensus on national science policy regarding recombinant DNA research. He served as founding director of the Whitehead Institute for Biomedical Research at MIT from 1982 until 1990. He co-chaired the 1986 National Academy of Sciences committee on a National Strategy for AIDS and was appointed in 1996 to head the National Institutes of Health AIDS Vaccine Research Committee.
In addition to receiving the Nobel Prize, Baltimore's numerous honors include the 1999 National Medal of Science, election to the National Academy of Sciences in 1974, the Royal Society of London, and the French Academy of Sciences. For 2007/8, he is President of the AAAS. He has published more than 600 peer-reviewed articles.
孙洪业：精准医学分析工具如何使临床实践和临床研究成为可能
介绍了公司发展历程，全球的一些布局，基因组学数据分析项目获得权威认可，提到了再云端的中国精准医疗计划，标准化的精准医疗云平台，HIPAA合规的安全架构，提到了安全性和隐私保护。以及一些案例分享等。
3D类器官模型工具的开发和应用
近几年类器官技术发展迅速，被认为是生命科学领域最具有突破性的新兴前沿科学技术之一。一方面，类器官作为3D细胞培养物，具有代表器官的一些特性和功能。类器官的出现打破了传统伦理束缚，未来可能成为可靠的细胞来源之一。另一方面，相比于动物模型，其在生物转染和高通量筛选、组织器官发育、疾病研究、新药研发和再生医学等领域具有独特的优势。此外，类器官模型也能通过与芯片结合在多学科领域研究发挥重要的作用，因而3D类器官模型将成为未来药物研发、疾病诊断和研究的最具潜力的研究工具。 生物谷携手生命科学领域领先品牌康宁，邀请从事3D类器官技术研究领域的专家分享当下类器官模型的最新研究进展，促进类器官在不同学科领域间的学术交流，探讨类器官模型从科研走到临床面临的机遇和挑战。 主要话题：类器官培养技术体系、组织器官的体外功能性构建、类器官高通量药物筛选、类器官模型与肿瘤靶向治疗、类器官与器官芯片、类器官模型在疾病靶点开发、疾病诊断等方面的研究。 欢迎届时参会讨论，期待会后，可以促成不同研究组进一步的交流与合作！